Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibefradil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H known ✓ | O95180 | 10/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 1.00 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibefradil SCHEMBL22968530 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL6789173 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL39551 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7265837 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL30170543 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL29364574 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7708100 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL2230258 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL908985 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL120810 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4403176-A2 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | Ferring B.V. (NL) | 2024-07-24 | — | — | EP | claimed |
| WO-2024025973-A2 | DEVICES AND METHODS FOR CONTINUOUS DIELECTROPHORESIS CELL SORTING TO ISOLATE DIFFERENT POPULATIONS OF CELLS, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | claimed |
| US-20220387620-A1 | NANOSTRUCTURED DRUG DELIVERY SYSTEM AS A MULTIFUNCTIONAL PLATFORM FOR THERAPY | UNIVERSIDADE DE COIMBRA (PT) | 2022-12-08 | — | — | US | claimed |
| US-20220151918-A1 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | FERRING B.V. (NL) | 2022-05-19 | — | — | US | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4695226-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035409-A1 | BRINP2-DERIVED PEPTIDE COMPOSITIONS FOR TREATING OBESITY AND WEIGHT MANAGEMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-02-05 | — | — | US | disclosed |
| US-20220151918-A1 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | FERRING B.V. (NL) | 2022-05-19 | — | — | US | disclosed |
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3972596-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | Pfizer Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-109689058-B | Treatment and prevention of sleep disorders | 普渡制药公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| WO-2022019892-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | CACNA1H 2953/4885CACNA1G 2398/4885CACNA1I 2622/4885 |
| US-20260035409-A1 | BRINP2-DERIVED PEPTIDE COMPOSITIONS FOR TREATING OBESITY AND WEIGHT MANAGEMENT | L3MBTL1, L3MBTL4, THRAP3 | CACNA1H 3240/4885CACNA1G 3416/4885CACNA1I 3957/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | CACNA1H 436/4885CACNA1G 366/4885CACNA1I 627/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | CACNA1H 3464/4885CACNA1G 3145/4885CACNA1I 3746/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | CACNA1H 3880/4885CACNA1G 3925/4885CACNA1I 3961/4885 |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | MCL1, BCL9, RNASE1 | CACNA1H 4580/4885CACNA1G 4571/4885CACNA1I 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.